Evidence map›Paper›PMID 34790371›Full record

ArticleJournal of gastrointestinal oncology2021

Apatinib plus S-1 for previously treated, advanced gastric or gastro-oesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study.

Chao Jing, Zhigang Bai, Jun Zhang, Hongpeng Jiang, Xiaobao Yang, Shu Yan, Jie Yin, Jun Cai, Zhongtao Zhang, Wei Deng

Registry-linked trialOpen access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of gastrointestinal oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04338438 (Apatinib Plus S-1 for Advanced Gastric Cancer Refractory to Oxaliplatin Plus Capecitabine Combination Therapy), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04338438 phase2completednot on this map

Apatinib Plus S-1 for Advanced Gastric Cancer Refractory to Oxaliplatin Plus Capecitabine Combination Therapy: A Single-arm, Phase-2, Home-based Trial

TypeinterventionalSponsorBeijing Friendship HospitalRan2015 to 2020Enrolled37ConditionsGastric CancerArmsApatinib Mesylate tablets combined with S-1 capsules
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Chao JingDepartment of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Zhigang BaiDepartment of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Jun ZhangDepartment of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Hongpeng JiangDepartment of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Xiaobao YangDepartment of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Shu YanDepartment of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Jie YinDepartment of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Jun CaiDepartment of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Zhongtao ZhangDepartment of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Wei DengDepartment of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Capital Medical University · CNBeijing Friendship Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe current management of advanced gastric or gastro-oesophageal junction adenocarcinoma remains unsatisfactory. We investigated the efficacy and safety of the combination therapy of apatinib and S-1, considering the potential advantage of home-based treatment without hospital admission, in patients with platinum-refractory gastric or gastro-oesophageal junction adenocarcinoma.

methodsIn this open-label, single-arm, phase 2 trial, in each 21-day cycle, eligible patients received apatinib at an initial dose of 500 mg once daily continuously and S-1 at a dose of 40-60 mg twice daily on days 1-14 until the trail was discontinued disease progression, development of intolerable toxicity, or withdrawal of consent. The primary endpoints were progression-free survival. The secondary endpoints were objective response rates, disease control rates, and safety, and overall survival. This study was registered at ClinicalTrials.gov, NCT04338438.

resultsBetween April 2015 and May 2019, we included 37 patients with advanced gastric or gastro-oesophageal junction adenocarcinoma refractory to first-line platinum-containing therapy. At the data cutoff, the 6-month progression-free survival was 31.5%, the median progression-free survival and overall survival were 4.2 (95% CI: 3.50-4.90) months and 8.2 (95% CI: 4.69-11.71) months, respectively. Of 37 eligible patients, 8 (21.6%) patients reached objective responses, 31 (83.8%) patients reached disease control. Grade 3 or 4 adverse events occurred in 8 (21.6%) patients, including hand-foot syndrome, hypertension, and diarrhea, etc.

conclusionsThe combination of Apatinib and S-1 showed promising efficacy and manageable toxicity as a home-based, second-line therapy in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma, especially for the elder patients with poor performance status.

trial registrationNCT04338438.

Indexed as

apatinibMolecular targeted therapyS-1stomach neoplasms

Identifiers

PMID34790371
PMCPMC8576210
OpenAlexW3197132665

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.